SLC22A17 and hepatocellular carcinoma: Among the analyzed genes, SLC22A17 was significantly upregulated in HCC cell lines after treatment with the demethylating agent 5-aza-2’-deoxycytidine (5-Aza-dC) and the histone deacetylase inhibitor trichostatin A (TSA), corroborating the evidence that promoter hypomethylation is crucial for the activation of SLC22A17 [70].